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55131 Mainz, GermanySee Article, pages 725–733Cancer research and therapy have come a long way:
the ﬁeld started out in search of a ‘‘magic bullet” accord-
ing to Paul Ehrlich’s theory, and was hoping to identify
a target which was pivotal to signaling survival in trans-
formed cells. Indeed, certain diseases with monocausal
mutations were identiﬁed, and targeting of the muta-
tional products has helped in the design of treatment
strategies. In chronic myeloid leukemia (CML), the con-
stitutive activation of the tyrosine kinase BCR-ABL is
pathognomonic [1], and multiple BCR-ABL kinase
inhibitors (e.g. imatinib mesylate, dasatinib, nilotinib)
have been developed and successfully used in the treat-
ment of CML oﬀering near-normal life expectancy to
patients under continuous therapy. The success of these
compounds has inspired research in the ﬁeld of speciﬁc
kinase inhibitors. Subsequently, it was recognized that
the developed kinase inhibitors did not exhibit a high
degree of selectivity, but rather caused inhibition of sev-
eral kinases [2].
Unfortunately, the success of tyrosine kinase inhibi-
tion in haematological malignancies could not be readily
translated to solid tumors which exhibit a comparatively
high degree of genomic alterations of signaling path-
ways. Nevertheless, based on the high expression levels0168-8278/$36.00  2009 European Association for the Study of the Liver.
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lar carcinoma.of EGFR and HER-2 in solid tumors, EGFR inhibitors
such as geﬁtinib and erlotinib were developed. Their
implementation in various malignancies resulted in clin-
ically meaningful, although moderate improvement of
overall survival for diﬀerent tumor entities and they
were ﬁrst introduced for non-small-cell lung cancer [3].
Other tumor entities followed and currently eight kinase
inhibitors are FDA-approved. The indication for use
includes hepatocellular carcinoma (HCC), where a
major breakthrough was achieved in the SHARP trial
in 2008 which demonstrated improved survival in
patients with advanced HCC receiving sorafenib [4].
Sorafenib was shown to inhibit roughly 15 kinases at
nanomolar potency [2] supporting the concept that a
‘‘dirty inhibitory eﬀect” on multiple kinases rather than
on a single signaling molecule will lead to recognizable
responses in the treatment of solid organ tumors includ-
ing HCC [4]. As a consequence, the precise mode of
action of sorafenib needs further clariﬁcation.
The work presented by Newell and colleagues in the
current issue of the Journal of Hepatology [5] examines
the antineoplastic potential of combining sorafenib with
rapamycin, an inhibitor of the mTOR pathway, in
experimental hepatocarcinogenesis. In agreement with
an earlier study by Wang et al. [6], the combination of
the two compounds lead to an additive eﬀect with
respect to reduced cell proliferation, increased cancer
cell apoptosis and increased tumor necrosis in a xeno-
graft model of HCC. The combination of these two
agents is appealing since two independent signaling
pathways which have been both implicated in the path-
ophysiology of HCC are targeted [7]. While sorafenib
inhibits the Ras/Raf/MEK/Erk pathway [8], rapamycin
inhibits activation of the mTOR complex downstreamPublished by Elsevier B.V. All rights reserved.
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pathways promote proliferation in HCC [9]. Additional
evidence supporting the rationale of simultaneous inhi-
bition of more than one signaling pathway comes from
studies showing a compensatory overactivation of one
parallel growth promoting pathway following signal
inhibition of another. In this sense mTOR inhibition
can result in compensatory activation of the Ras signal-
ing pathway leading to cancer cell resistance [10] and
thus, additional Ras inhibition potentially counteracts
such a compensatory mechanism.
Apart from the biological response in the xenograft
model, the authors found changes in methylation pat-
terns of oncogens of the Ras pathway in advanced
tumor stages. It is diﬃcult to assess the biological mean-
ing of such observations and it is likely that many
changes that are seen in dediﬀerentiated tumor tissue
occur without signiﬁcantly contributing to tumor biol-
ogy and thus the relevance of those in vitro ﬁndings in
predicting potential targets or markers that can be use-
ful in clinical trials is questionable.
In order to separate signal from noise, to identify pre-
dominant signaling pathways in solid tumors, deﬁning
tumor biology, the concept of oncogenic addiction has
been developed [11]. This concept was derived from
observations revealing tumorous tissue to be dependent
on only one or a few genes for cell survival and main-
taining the malignant phenotype despite a high degree
of genetic and epigenetic abnormalities [11]. Identiﬁca-
tion of these pivotal pathways which are crucial to
tumor cell survival will advance the success in the treat-
ment of HCC rapidly. In addition to the above men-
tioned pathways, important targets to be assessed for
combination therapy include the Wnt/b-catenin path-
way, cell cycle regulators (CDK), angiogenic factors
(VEGFR and PDGFR) and proteases such as MMP-
14, MMP-9 or topoisomerase [12]. As long as tumor
deﬁning signaling pathways can not be deﬁned precisely
enough to develop highly selective inhibitors of down-
stream targets aimed to inhibit the oncogenes, which
are crucial to tumor cell growth, low selectivity as seen
with sorafenib will help to achieve an anti-tumor eﬀects
despite the lack of knowledge of the exact mechanisms.
Moreover, the combined inhibition through unspeciﬁci-
ty or the addition of a second pathway inhibitor might
help to overcome resistance attributable to activation
of multiple cell growth pathways. The challenge of
future research in this ﬁeld will be to engineer reliable
systems that predict targets which will lead to inhibition
of the pathway the tumor ‘‘is addicted to”. In the age
past the ‘‘Human Genome Project” tumor biology will
have to develop treatment strategies detached from adeterministic, genetic view and produce ‘‘pathway ﬁn-
gerprints” of a tumor which can predict the individual-
ized response towards inhibition of kinases or
combinations thereof. These concepts will rely on sys-
tem biology which will help to predict the response of
tumors to pathway inhibition depending on the predom-
inant tumor biology and to deﬁne future targets of
therapy.
However the biggest challenge will remain, regardless
how good the rationale for testing drugs has been elab-
orated in vitro: clinical trials still have to be used in the
end to deﬁne the beneﬁt for the patient and here we have
seen many surprises of success and failure previously not
predicted on theoretical grounds.References
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